Invasive Sarcomatoid Urothelial Carcinoma — knowledge graph · CancerIndex

Knowledge graph · Cancer

Invasive Sarcomatoid Urothelial Carcinoma

subtype

Identifier: CI-CAN-00005633
Entity page: /cancer/invasive-sarcomatoid-urothelial-carcinoma ↗
Edges: 20

Neighbours: 14 drugs6 trials
Drawn: 20 of 20 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Invasive Sarcomatoid Urothelial Carcinoma investigated in trials for …INVESTIGATED_IN_TRIALSderived14 of 14
→ investigated in trials for	Durvalumabmonoclonal antibody 3 trials (2 active) · roll-up of the cancer and its descendants	—	—	Invasive Sarcomatoid Urothelial Carcinoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Cabozantinibsmall molecule 2 trials (2 active) · roll-up of the cancer and its descendants

Invasive Sarcomatoid Urothelial Carcinoma studied in …STUDIED_INderived6 of 6
→ studied in	NCT03866382Phase 2 · recruiting Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors · condition mapped ONTOLOGY_EXACT · 6 trials mapped (5 active)	—	—	Invasive Bladder Sarcomatoid Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02812420early Phase 1 · active not recruiting Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery · condition mapped ALIAS · 6 trials mapped (5 active)	—	—	Invasive Bladder Sarcomatoid Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02496208Phase 1 · active not recruiting Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors · condition mapped ONTOLOGY_EXACT · 6 trials mapped (5 active)	—	—	Invasive Sarcomatoid Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03744793Phase 2 · active not recruiting Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer · condition mapped ALIAS · 6 trials mapped (5 active)	—	—	Invasive Bladder Sarcomatoid Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05154994Phase 1 · active not recruiting Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma · condition mapped ALIAS · 6 trials mapped (5 active)	—	—	Invasive Sarcomatoid Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03912818Phase 2 · terminated Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer · condition mapped ALIAS · 6 trials mapped (5 active)	—	—	Invasive Bladder Sarcomatoid Urothelial Carcinoma	1	Observed	clinicaltrials	graph →